Does Growth Hormone Replacement Therapy Reduce Mortality in Adults with Growth Hormone Deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in Adults
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Context: Adults with GH deficiency (GHD) have a decreased life expectancy. The effect of GH treatment on mortality remains to be established. Objective: This nationwide cohort study investigates the effect of GH treatment on all-cause and cause-specific mortality and analyzes patient characteristics influencing mortality in GHD adults. Design, Setting, and Patients: Patients in the Dutch National Registry of Growth Hormone Treatment in Adults were retrospectively monitored (1985–2009) and subdivided into treatment (n = 2229), primary (untreated, n = 109), and secondary control (partly treated, n = 356) groups. Main Outcome Measures: Standardized mortality ratios (SMR) were calculated for all-cause, malignancy, and cardiovascular disease (CVD) mortality. Expected mortality was obtained from cause, sex, calendar year, and age-specific death rates from national death and population counts. Results: In the treatment group, 95 patients died compared to 74.6 expected [SMR 1.27 (95% confidence interval, 1.04–1.56)]. Mortality was higher in women than in men. After exclusion of high-risk patients, the SMR for CVD mortality remained increased in women. Mortality due to malignancies was not elevated. In the control groups mortality was not different from the background population. Univariate analyses demonstrated sex, GHD onset, age, and underlying diagnosis as influencing factors. Conclusions: GHD men receiving GH treatment have a mortality rate not different from the background population. In women, after exclusion of high-risk patients, mortality was not different from the background population except for CVD. Mortality due to malignancies was not elevated in adults receiving GH treatment. Next to gender, the heterogeneous etiology is of influence on mortality in GHD adults with GH treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 1×
“Patients with adult onset GHD have a decreased life expectancy due to an increased mortality from cardiovascular diseases.(2) Important changes in cardiovascular risk factors, such as adverse lipid profile, increased body mass index, and hypertension in GHD are reported, but also reduced exercise tolerance, osteoporos…”
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
Carroll, P. V., Christ the members of Growth Hormon, E. R., Bengtsson, B. Å., Carlsson, L., Christiansen, J. S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4594 · Cited by 822
Increased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
The effect of hypopituitarism on life expectancy.
Bates, A. S., Van't Hoff, W., Jones, P. J., & Clayton, R. N. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772595 · Cited by 475 · cited 1×
“In hypopituitarism a gender difference has been described several times.(17;18;20;27;28) There is data indicating GHD men are more responsive to GH treatment than women with respect to increase in IGF-1 levels and improvement of body composition.”
The growth hormone deficiency syndrome in adults
Cuneo, R. C., Salomon, F., McGauley, G. A., & Sönksen, P. H. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02347.x · Cited by 375 · cited 1×
“Important changes in cardiovascular risk factors, such as adverse lipid profile, increased body mass index, and hypertension in GHD are reported, but also reduced exercise tolerance, osteoporosis, and reduced quality of life.(1;3) The most common underlying causes of GHD in adults are pituitary adenomas or the consequ…”
Long-term safety of recombinant human growth hormone in children
Bell, J., Parker, K. L., Swinford, R. D., Hoffman, A. R., Maneatis, T., & Lippe, B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0178 · Cited by 301 · cited 1×
“A study in children having received GH treatment raised some concern on development of malignancies,(22) but other studies were contradicting.(23;24) A recent review on safety aspects of GH treatment in adults reports no increase in cancer risk in a large surveillance study,(25) nor was there an association between ca…”
Span, J. P. T., Pieters, G. F. F. M., Sweep, C. G. J., Hermus, A. R. M. M., & Smals, A. G. H. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6463 · Cited by 132 · cited 1×
“Also, estrogen replacement in GHD women weakens the IGF-1 response to GH treatment, whereas in men androgen replacement increases the responsiveness.(31) In our study all patients have received GH treatment with individualized dosage depending on IGF-1 values.”
Hypopituitarism and mortality in pituitary adenoma
Lindholm, J., Nielsen, E. H., Bjerre, P., Christiansen, J. S., Hagen, C., Juul, S., Jørgensen, J., Kruse, A., Laurberg, P., & Stochholm, K. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02545.x · Cited by 68
Cited by
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Higham, C. E., Johannsson, G., & Shalet, S. M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30053-8 · Cited by 267
Burman, P., Mattsson, A. F., Johannsson, G., Höybye, C., Holmer, H., Dahlqvist, P., Berinder, K., Engström, B. E., Ekman, B., Erfurth, E. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4059 · Cited by 184
“Malignancyrelated death has been reported to be either similar (3, 4, 6, 7) or increased, in particular, in young subjects (5, 8–10).”
Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study
Swerdlow, A. J., Cooke, R., Beckers, D., Borgström, B., Butler, G., Carel, J.-C., Cianfarani, S., Clayton, P., Coste, J., Deodati, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2046 · Cited by 153
“Previous large r-hGH cohorts, with one exception (16), have censored follow-up at last clinic visit, not at a fixed end-date (10, 12, 13, 26).”
Background
Metadata
- Authors
- van Bunderen, C. C., van Nieuwpoort, I. C., Arwert, L. I., Heymans, M. W., Franken, A. A. M., Koppeschaar, H. P. F., van der Lely, A. J., & Drent, M. L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-10-01
- Volume
- 96
- Issue
- 10
- Pages
- 3151-3159
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2059065431
- Cited by
- 133
- References
- 8
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.